Results 101 to 110 of about 577,312 (257)

APPLICATIONS OF FAIR VALUE PRICING [PDF]

Challenges of the Knowledge Society, 2019
The 2008 crisis prolonged and deepened divergences in fair value measurement as the most reliable and other measurement systems. The introduction of IFRS 13 contributed to improved results at the level 3 asset prices observed in companies operating on ...
Valentin Gabriel CRISTEA
doaj  

Managing Metadata Towards Enhanced Data Quality in Asset Management

, 2011
In engineering asset management (AM) organisations, a variety of data types ranging from asset monitoring data to asset documentation needs to be constantly managed to ensure optimal performance of the underlying infrastructure and engineering assets ...
Lubos Vnuk, Vnuk, L., Jing Gao, Andy Koronios, Koronios, A., Gao, J.   +5 more
core   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

ASSET project outcome evaluation report in Cambodia

This outcome evaluation applies a complexity-aware, systemic approach to assess the Agroecology and Safe Food System Transitions (ASSET) project in Cambodia, with a focus on its implementation in Preah Vihear and Battambang provinces.
Chou, Phanith, Alexandre, Chloé, Castella, Jean-Christophe, Blundo Canto, Genowefa, Kong, Rada   +4 more
core  

Asset Lifecycle Data Governance Framework

, 2014
Engineering asset lifecycle management is information intensive. The variety of asset lifecycle processes generate, process, and analyze enormous amount of data on daily basis.
Abrar Haider, Haider, A.
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

The Classification and Identification of Asset Price Bubbles [PDF]

This article briefly summarizes approaches to and options for identifying bubbles in asset prices. Further, the article draws on bubble literature and it theoretically discusses classification of asset price bubbles according to features as differences ...
Lubos Komarek, Ivana Kubicová
core  

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Changes in Risk and Asset Prices [PDF]

We examine asset prices in a representative-agent model of general equilibrium. Assuming only that individuals are risk averse, we determine conditions on the changes in asset risk that are both necessary and sufficient for the asset price to fall.
Christian Gollier, Harris Schlesinger
core  

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source